RTx-303
RTx-303 is an orally active, selective DNA polymerase θ (Polθ) inhibitor (IC50 = 5.1 nM) . RTx-303 exhibits significantly high cellular potency and strongly potentiates PARPi in BRCA1/2 mutant cells and patient-derived xenograft models. RTx-303 can be used for the study of BRCA2-mutated breast cancer[1].
Product Specifications
CAS Number
3035072-99-9
UNSPSC
12352005
Target
DNA/RNA Synthesis
Related Pathways
Cell Cycle/DNA Damage
Field of Research
Cancer
Smiles
CN(C)C[C@@H](O)CN(C1=O)CCN1C2=C(OC(N(C([2H])([2H])[2H])C3=CC=C(F)C=C3)=O)C(C(F)(F)F)=CC(C(F)(F)F)=C2
Molecular Formula
C24H22D3F7N4O4
Molecular Weight
569.49
References & Citations
[1]Chandramouly G, et al. RTx-303, an Orally Bioavailable Polθ Polymerase Inhibitor That Potentiates PARP Inhibitors in BRCA Mutant Tumors. J Med Chem. 2025 Nov 13;68 (21) :22196-22215.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
C5062-69A-PE 200 µL
CHK, CT (Choline Kinase alpha, CK, CHETK-alpha, Ethanolamine Kinase, EK, CHKA, CKI) (PE) discontinued
Sign In for Pricing
View Details 